Pathogen News and Research

RSS

Bacterial DNA reveals a rise in antibiotic resistant genes

Antibiotic resistance in the natural environment is rising despite tighter controls over our use of antibiotics in medicine and agriculture, Newcastle University scientists have found.

24 Dec 2009

AdvanDx receives FDA clearance for its 90 minutes PNA FISH protocol

AdvanDx today announced that it has received FDA 510(k) clearance for a fast, 90 minutes protocol for its E. coli/P. aeruginosa PNA FISH® and EK/P. aeruginosa PNA FISH® tests. The faster protocol reduces the PNA FISH turn-around time from the original 2.5 hours to 90 minutes by reducing PNA probe hybridization from 90 minutes to 30 minutes.

22 Dec 2009

Researchers identify new method to tackle bacterial infections

Researchers from the University of Groningen have clarified the structure of an enzyme that disturbs the communication processes between bacteria. By doing so they have laid the foundations for a new method of tackling bacterial infections such as cystic fibrosis.

22 Dec 2009

New findings reveal POPG lipid can prevent RSV infection in lungs

Researchers at National Jewish Health have discovered that a naturally occurring lipid in the lung can prevent RSV infection and inhibit spread of the virus after an infection is established. RSV is the major cause of hospitalization for children in the first two years of life, and is increasingly recognized as a dangerous pathogen in adults with chronic lung diseases, the elderly, and immunocompromised individuals. Currently, there is no effective vaccine for the virus.

22 Dec 2009

TessArae's RM-Flu test granted FDA EUA

TessArae, LLC, a privately held company, and Affymetrix Inc., (NASDAQ:AFFX) today announced that the Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) to TessArae for its TessArray® Resequencing Influenza A Microarray Detection Panel for the Detection of the 2009 H1N1 Influenza A Virus (TessArray RM-Flu test) for the duration of the declaration of emergency unless revoked earlier. The declaration of emergency will expire on April 26, 2010, unless terminated earlier or renewed.

21 Dec 2009

Human protein may help prevent H1N1 infection

Howard Hughes Medical Institute researchers have identified a naturally occurring human protein that helps prevent infection by H1N1 influenza and other viruses, including West Nile and dengue virus.

18 Dec 2009

Study explains Salmonella's infection strategy

Salmonella are highly adaptive bacteria. They can live in the presence and absence of oxygen and thus propagate in the gut. The ingestion by humans occurs mainly via contaminated egg dishes such as mayonnaise or raw milk products as well as meat or sausages. Infections with Salmonella lead to severe diarrhea and fever, particularly in patients harbouring a compromised immune system.

17 Dec 2009

Pomegranate rind, metal salts and Vitamin C: An effective combination for treating MRSA infection

Pomegranates have already been hailed as a super-food but a team of scientists from Kingston University in South West London has found a new use for the deep red fruit. The team, led by Professor Declan Naughton, has discovered that the rind can be turned into an ointment for treating MRSA and other common hospital infections.

16 Dec 2009

MRSA, the most concerning pathogen to surveyed for skin and skin structure infections

Arlington Medical Resources (AMR) and Decision Resources find that methicillin-resistant Staphylococcus aureus (MRSA) is the most concerning pathogen to surveyed European infectious disease specialists with regard to their treatment of skin and skin structure infections.

16 Dec 2009

Freie Universität professor receives ERC grant for bacterial biofilm formation study

Prof. Dr. Regine Hengge at the Department of Biology, Chemistry, and Pharmacy at Freie Universität Berlin has been awarded funding from the European Research Council (ERC) for her research project to investigate the formation of bacterial biofilms. Hengge will receive an ERC Advanced Investigator Grant in an amount of up to two million euros.

15 Dec 2009

Cubist Pharmaceuticals signs definitive agreement to acquire Calixa Therapeutics

Cubist Pharmaceuticals, Inc. a leading acute care therapeutics company, announced today the signing of a definitive agreement under which Cubist has agreed to acquire privately held Calixa Therapeutics Inc., a biopharmaceutical company focused on the development of novel antibiotics that address the expanding problem of multi-drug resistant Gram-negative pathogens.

14 Dec 2009

NIH awards $14.6M for Eukaryotic Pathogen Genome Database Resource expansion

Researchers from the University of Pennsylvania and the University of Georgia have been awarded a five-year, $14.6 million contract from the National Institute of Allergy and Infectious Diseases, part of the US National Institutes of Health, to expand and extend work on the Eukaryotic Pathogen Genome Database Resource, http://EuPathDB.org.

11 Dec 2009

Biomagnetics Diagnostics discusses utilization of acquired Los Alamos National Security intellectual property

Biomagnetics Diagnostics Corp., a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis and malaria detection provides the following recap of yesterday's investor conference call, which discussed the Company’s acquisition of intellectual property rights from Los Alamos National Security.

5 Dec 2009

Guidelines to diagnose and manage complicated skin and soft tissue infections published

New evidence-based recommendations developed by the Surgical Infection Society to guide physicians in the diagnosis and management of complicated skin and soft tissue infections have been published in Surgical Infections, a peer-reviewed journal published by Mary Ann Liebert, Inc. (www.liebertpub.com).

3 Dec 2009

International AIDS Vaccine Initiative calls for redoubled efforts in vaccine development

As we approach World AIDS Day, observed globally December 1, we are reminded that while progress has been made in expanding access to treatment and prevention and that progress has been made toward the development of new prevention tools, the world is still falling short of established targets for providing universal access to HIV and AIDS prevention, treatment and care by 2010. Nearly 5.5 million of the estimated 9.5 million people in need of antiretroviral therapy are still not receiving it.

2 Dec 2009

FDA approves additional intended use of Roche's cobas TaqScreen MPX Test

Roche announced today that the United States Food & Drug Administration (FDA) approved an additional intended use for its licensed nucleic acid test, to screen source plasma in pools comprised of up to 96 individual donations. The test, called the cobas® TaqScreen MPX Test for use on the cobas s 201 system, is a qualitative, in-vitro test for the simultaneous, direct detection of the human immunodeficiency virus (HIV-1 Group M RNA, HIV-1 Group O RNA , HIV-2 RNA), hepatitis C virus RNA and hepatitis B virus DNA in human plasma.

From Roche Sequencing and Life Science 2 Dec 2009

Canadians with hemophilia A can use new treatment option, XYNTHA

Canadians with hemophilia A - a rare, inherited blood-clotting disorder - now have a new treatment option with the introduction of XYNTHA(TM), a recombinant factor VIII product for both the control and prevention of bleeding episodes and surgical prophylaxis.

2 Dec 2009

Roche's MagNA Pure 96 System for nucleic acid purification evaluated

TriCore Reference Laboratories of Albuquerque, N.M., reported at a recent user meeting results of their research collaboration with Roche Applied Science in which they evaluated Roche´s new MagNA Pure 96 System for use in nucleic acid purification. The evaluation focused on the Roche system’s ability to process specimens for pathogen testing.

1 Dec 2009

New form of pathogen becomes a healthcare challenge in Africa

Research shows how a new, more deadly strain of Salmonella emerged over an 18-month period. Becoming resistant to antibiotics, acquiring the ability to spread from person to person and losing genes along the way, the new strain has become a healthcare challenge in Africa, killing up to one in four patients.

1 Dec 2009

Biomagnetics Diagnostics announces Patent License Agreement with Los Alamos National Security

Biomagnetics Diagnostics Corp. (PINK SHEETS:BMGP), a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis and malaria detection, today announced the Company has finalized a "Patent License Agreement with Los Alamos National Security."

30 Nov 2009

Pathogen News and Research

Bacterial DNA reveals a rise in antibiotic resistant genes

AdvanDx receives FDA clearance for its 90 minutes PNA FISH protocol

Researchers identify new method to tackle bacterial infections

New findings reveal POPG lipid can prevent RSV infection in lungs

TessArae's RM-Flu test granted FDA EUA

Human protein may help prevent H1N1 infection

Study explains Salmonella's infection strategy

Pomegranate rind, metal salts and Vitamin C: An effective combination for treating MRSA infection

MRSA, the most concerning pathogen to surveyed for skin and skin structure infections

Freie Universität professor receives ERC grant for bacterial biofilm formation study

Cubist Pharmaceuticals signs definitive agreement to acquire Calixa Therapeutics

NIH awards $14.6M for Eukaryotic Pathogen Genome Database Resource expansion

Biomagnetics Diagnostics discusses utilization of acquired Los Alamos National Security intellectual property

Guidelines to diagnose and manage complicated skin and soft tissue infections published

International AIDS Vaccine Initiative calls for redoubled efforts in vaccine development

FDA approves additional intended use of Roche's cobas TaqScreen MPX Test

Canadians with hemophilia A can use new treatment option, XYNTHA

Roche's MagNA Pure 96 System for nucleic acid purification evaluated

New form of pathogen becomes a healthcare challenge in Africa

Biomagnetics Diagnostics announces Patent License Agreement with Los Alamos National Security

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest Life Science News